At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Abemaciclib for Mantle Cell Lymphoma. Completed, enrolled 28 participants across 7 sites in 2 countries.
Detailed Summary
The purpose of this study is to estimate the disease control rate with abemaciclib for relapsed or refractory mantle cell lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMantle Cell Lymphoma
CountriesFrance, Germany
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartMar 2013
Primary CompletionSep 2015
Study CompletionSep 2022
TodayJul 2026
First PostedDec 3, 2012
Enrollment StartMar 20, 2013
Primary CompletionSep 28, 2015
Study CompletionSep 5, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 13.6 years ago
Interventions
Abemaciclibdrug
Administered orally